The Key Biomarkers Changing How and When We Diagnose Alzheimer’s Disease
Innovations in biomarker science, particularly in cerebrospinal fluid (CSF) and blood, are expanding Alzheimer’s testing beyond specialty care.
The End of Incrementalism: Why Healthcare Innovation is Finally Reshaping the Model
The difference between that last era and this one isn’t incremental. It’s categorical. Artificial intelligence isn’t optimizing the old system. It’s making the old system economically indefensible.
New Bill Seeks to Lower Out-of-Pocket Drug Costs
Rep. Greg Murphy introduced a bill that would require out-of-pocket prescription drug spending to count toward patients’ deductibles and out-of-pocket maximums regardless of where the drugs are purchased.
Why Innovaccer Is Pouring $250M into Its Agentic AI Platform
Innovaccer is committing $250 million to expand its AI agent platform, which automates workflows across areas like prior authorization, revenue cycle management and population health. The move comes amid an ongoing debate over whether administrative AI tools can ultimately reduce costs for providers.
Eli Lilly Buys Startup CrossBridge Bio to Bring a More Powerful Strike to Tumors
Eli Lilly is paying up to $300 million for CrossBridge Bio, a startup developing antibody drug conjugates that deliver two drug payloads to cancers. Beyond potentially better efficacy, CrossBio’s dual approach could also fight drug resistance.